Opko Health Inc Stock News

OPKO Health's (OPK) first-quarter results reflect soft performances despite robust RAYALDEE sales and strength in the Pharmaceuticals segment.

Although the revenue and EPS for OPKO Health (OPK) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Stre

Start Time: 16:30 January 1, 0000 5:21 PM ET OPKO Health, Inc. (NASDAQ:OPK ) Q1 2024 Earnings Conference Call May 07, 2024, 16:30 PM ET Company Participants Phil Frost - Chairman and CEO Elias Zerhoun

OPKO Health (OPK) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.02 per share a year ago.

MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2024. First quarter business highlights i

MIAMI, May 03, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2024 after the close of the U.S. financial

OPKO Health (OPK) expects to re-establish profitability in its clinical laboratory business via its latest efforts to streamline its laboratory services business.

Transaction to enhance Labcorp's laboratory services network  and expand access to the company's high-quality clinical laboratory services BURLINGTON, N.C. and MIAMI , March 28, 2024 /PRNewswire/ --�

OPKO Health (OPK) and Entera Bio announce robust pharmacokinetic results for the proprietary GLP-2 agonist developed by OPK Heath.

• Study delivers first clinical safety and pharmacokinetic data as proof of concept for the use of multispecific antibodies in humans • Candidate showed similar half-life to standard monoclonal a

Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall fourth-quarter results reflect soft performances.

While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics com

OPKO Health, Inc. (OPK) Q4 2023 Earnings Call Transcript

OPKO Health (OPK) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.11 per share a year ago.

MIAMI, Feb. 27, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2023. Business highlights from